|
1
|
Shima Y and Kitabayashi I: Deregulated
transcription factors in leukemia. Int J Hematol. 94:134–141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Döhner K and Döhner H: Molecular
characterization of acute myeloid leukemia. Haematologica.
93:976–982. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vardiman J and Hyjek E: World health
organization classification, evaluation, and genetics of the
myeloproliferative neoplasm variants. Hematology Am Soc Hematol
Educ Program. 2011:250–256. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Strathdee G, Holyoake TL, Sim A, et al:
Inactivation of HOXA genes by hypermethylation in myeloid and
lymphoid malignancy is frequent and associated with poor prognosis.
Clin Cancer Res. 13:5048–5055. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shah N and Sukumar S: The Hox genes and
their roles in oncogenesis. Nat Rev Cancer. 10:361–371. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Argiropoulos B and Humphries RK: Hox genes
in hematopoiesis and leukemogenesis. Oncogene. 26:6766–6776. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fournier M, Lebert-Ghali CÉ, Krosl G and
Bijl JJ: HOXA4 induces expansion of hematopoietic stem cells in
vitro and confers enhancement of pro-B-cells in vivo. Stem Cells
Dev. 21:133–142. 2012. View Article : Google Scholar
|
|
8
|
Iacovino M, Hernandez C, Xu Z, Bajwa G,
Prather M and Kyba M: A conserved role for Hox paralog group 4 in
regulation of hematopoietic progenitors. Stem Cells Dev.
18:783–792. 2009. View Article : Google Scholar :
|
|
9
|
Fuller JF, McAdara J, Yaron Y, Sakaguchi
M, Fraser JK and Gasson JC: Characterization of HOX gene expression
during myelopoiesis: role of HOX A5 in lineage commitment and
maturation. Blood. 93:3391–3400. 1999.PubMed/NCBI
|
|
10
|
Crooks GM, Fuller J, Petersen D, Izadi P,
Malik P, Pattengale PK, et al: Constitutive HOXA5 expression
inhibits erythropoiesis and increases myelopoiesis from human
hematopoietic progenitors. Blood. 94:519–528. 1999.PubMed/NCBI
|
|
11
|
Argiropoulos B, Yung E and Humphries RK:
Unraveling the crucial roles of Meis1 in leukemogenesis and normal
hematopoiesis. Genes Dev. 21:2845–2849. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zangenberg M, Grubach L, Aggerholm A,
Silkjaer T, Juhl-Christensen C, Nyvold CG, et al: The combined
expression of HOXA4 and MEIS1 is an independent prognostic factor
in patients with AML. Eur J Haematol. 83:439–448. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim SY, Hwang S-H, Song EJ, Shin HJ, Jung
JS and Lee EY: Level of HOXA5 hypermethylation in acute myeloid
leukemia is associated with short-term outcome. Korean J Lab Med.
30:469–473. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Walker H, Smith FJ and Betts DR:
Cytogenetics in acute myeloid leukaemia. Blood Rev. 8:30–36. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Strathdee G, Sim A, Soutar R, Holyoake TL
and Brown R: HOXA5 is targeted by cell-type-specific CpG island
methylation in normal cells and during the development of acute
myeloid leukaemia. Carcinogenesis. 28:299–309. 2007. View Article : Google Scholar
|
|
16
|
Lasa A, Carnicer MJ, Aventín A, Estivill
C, Brunet S, Sierra J, et al: MEIS 1 expression is downregulated
through promoter hypermethylation in AML1-ETO acute myeloid
leukemias. Leukemia. 18:1231–1237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Strathdee G, Sim A, Parker A, Oscier D and
Brown R: Promoter hypermethylation silences expression of the HoxA4
gene and correlates with IgVh mutational status in CLL. Leukemia.
20:1326–1329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tholouli E, MacDermott S, Hoyland J, Yin
JL and Byers R: Quantitative multiplex quantum dot in-situ
hybridisation based gene expression profiling in tissue microarrays
identifies prognostic genes in acute myeloid leukaemia. Biochem
Biophys Res Commun. 425:333–339. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Grubach L, Juhl-Christensen C, Rethmeier
A, et al: Gene expression profiling of Polycomb, Hox and Meis genes
in patients with acute myeloid leukaemia. Eur J Haematol.
81:112–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bullinger L, Döhner K, Bair E, et al: Use
of gene-expression profiling to identify prognostic subclasses in
adult acute myeloid leukemia. N Engl J Med. 350:1605–1616. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grubach L, Juhl-Christensen C, Rethmeier
A, et al: Gene expression profiling of Polycomb, Hox and Meis genes
in patients with acute myeloid leukaemia. Eur J Haematol.
81:112–122. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thompson A, Quinn MF, Grimwade D, et al:
Global down-regulation of HOX gene expression in PML-RARalpha+acute
promyelocytic leukemia identified by small-array real-time PCR.
Blood. 101:1558–1565. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Andreeff M, Ruvolo V, Gadgil S, et al: HOX
expression patterns identify a common signature for favorable AML.
Leukemia. 22:2041–2047. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Debernardi S, Lillington DM, Chaplin T, et
al: Genome-wide analysis of acute myeloid leukemia with normal
karyotype reveals a unique pattern of homeobox gene expression
distinct from those with translocation-mediated fusion events.
Genes Chromosomes Cancer. 37:149–158. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Roche J, Zeng C, Barón A, et al: Hox
expression in AML identifies a distinct subset of patients with
intermediate cytogenetics. Leukemia. 18:1059–1063. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Verhaak RG, Goudswaard CS, van Putten W,
et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia
(AML): association with other gene abnormalities and previously
established gene expression signatures and their favorable
prognostic significance. Blood. 106:3747–3754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bacher U, Kohlmann A, Haferlach C and
Haferlach T: Gene expression profiling in acute myeloid leukaemia
(AML). Best Pract Res Clin Haematol. 22:169–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Whitman SP, Maharry K, Radmacher MD, et
al: FLT3 internal tandem duplication associates with adverse
outcome and gene- and microRNA-expression signatures in patients 60
years of age or older with primary cytogenetically normal acute
myeloid leukemia: a Cancer and Leukemia Group B study. Blood.
116:3622–3626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Drabkin HA, Parsy C, Ferguson K, Guilhot
F, et al: Quantitative HOX expression in chromosomally defined
subsets of acute myelogenous leukemia. Leukemia. 16:186–195. 2002.
View Article : Google Scholar : PubMed/NCBI
|
